Empagliflozin's CV Benefit Impresses At EASD, But What Will FDA Say?
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer/Lilly's Jardiance delivers impressive CV death benefit but no effect on myocardial infarction or stroke – prompting questions about relevance of MACE composite primary endpoint.